Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aneuryst Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution for the company's current biological or medical technology. The concentration in 1 art unit suggests that the pending application is specialized within the pharmaceutical field.
The busiest examiner, RAO, PADMAJA S, is currently managing 1 busiest examiner pending action. As this is the only pending action in the portfolio, the prosecution outcome is dependent on the review conducted by this specific examiner. Practitioners should focus on the technical requirements of the 1 art unit to ensure an effective response. The presence of only 1 pending action simplifies the administrative burden, as the company does not need to coordinate across different examiners or pending deadlines at this time. This allows for a concentrated effort on the 1 pending office action within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316258 | TREATMENTS FOR DISTURBED CEREBRAL HOMEOSTASIS | RAO, PADMAJA S | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316258 | TREATMENTS FOR DISTURBED CEREBRAL HOMEOSTASIS | RAO, PADMAJA S | 41d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18316258 | TREATMENTS FOR DISTURBED CEREBRAL HOMEOSTASIS | RAO, PADMAJA S | 1627 | §102§103§112Other | Non-Final OA | 41d | Pending | May 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAneuryst Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Padmaja S Rao has the most, with 1 of Aneuryst Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.